1204400-34-9

Basic information

• Product Name: 4-(3,4-difluorobenzyl)-3-oxo-3,4-dihydropyrazine-2-carboxyIic acid
• Synonyms: 4-(3,4-difluorobenzyl)-3-oxo-3,4-dihydropyrazine-2-carboxyIic acid
• CAS NO: 1204400-34-9
• Molecular Weight: 266.204
• Mol File: 1204400-34-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(3,4-difluorobenzyl)-3-oxo-3,4-dihydropyrazine-2-carboxyIic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-difluorobenzyl)-3-oxo-3,4-dihydropyrazine-2-carboxyIic acid(1204400-34-9)
• EPA Substance Registry System: 4-(3,4-difluorobenzyl)-3-oxo-3,4-dihydropyrazine-2-carboxyIic acid(1204400-34-9)

Safety Data

• Hazardous Substances Data: 1204400-34-9(Hazardous Substances Data)

Upstream product

• 20737-42-2 3-oxo-3,4-dihydropyrazine-2-carboxylic acid 
• 5424-01-1 3-aminopyrazinoic acid 
• 1204400-32-7 methyl 4-(3,4-difluorobenzyl)-3-oxo-3,4-dihydiropyrazine-2-carboxylate 

Downstream Products

• 1228657-08-6 4-(3,4-difluorobenzyl)-3-oxo-N-{(1R)-2-[(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)oxy]-1-phenylethyl}-3,4-dihydropyrazine-2-carboxamide 

Relevant articles and documents

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1)

The instant invention provides for compounds that inhibit PDK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting PDK1 activity by administering the compound to a patient in need of treatment of cancer.